Skip to main content
Erschienen in: Clinical and Translational Oncology 11/2020

22.05.2020 | Research Article

Safety in radiation oncology: transposition of directive 2013/59/EURATOM in the Spanish Radiation Oncology Departments—recommendations for its adequate and effective application

verfasst von: J. Pardo Masferrer, C. Prieto Martín, C. Ferrer Albiach

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The Official Journal of the European Union published on January 17, 2014 the Council Directive 2013/59/EURATOM of December 5, 2013, which establishes basic safety standards for the protection against the dangers derived from the exposure to ionizing radiation, and should have been transposed to the regulations of the member countries of the European Union.

Methods

We carried out and exhaustive review of the Directive, to highlight its aspects referred to radiotherapy, in order to issue recommendations for its adequate and effective application in Spain.

Recommendations for its transposition

A series of recommendations are issued, from highest to lowest organizational level: Legislative, Scientific Societies, Healthcare Centers, Radiation Oncology Departments, Radiation Oncologists and Patients.

Conclusions

The implementation of what the transposition of the Directive to our legal order implies, besides the implication of the professionals, Centers and Administration, a need and a consumption of resources. If not enough are allocated, there is a risk that the innovation and improvement that the transposition would imply in order to raise the level of patient safety and the quality of Radiation Oncology in Spain will remain a paper tiger and, as the Romans said, “Non progredi est regredi”, that is, when it does not go forward, it goes backwards.
Literatur
1.
Zurück zum Zitat Council Directive 2013/59/Euratom of 5 December 2013, laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Official Journal of the European Union. 17 of January 2013. Council Directive 2013/59/Euratom of 5 December 2013, laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Official Journal of the European Union. 17 of January 2013.
2.
Zurück zum Zitat Royal Decree 783/2001, of July 6, which approves the Regulation on sanitary protection against ionizing radiation. BOE nº 178 of July 26, 2001. p 27284-27393. Royal Decree 783/2001, of July 6, which approves the Regulation on sanitary protection against ionizing radiation. BOE nº 178 of July 26, 2001. p 27284-27393.
3.
Zurück zum Zitat Instruction IS-33, of December 21, 2011, from the Nuclear Safety Council, on radiological criteria for protection against exposure to natural radiation. BOE nº 22 of January 26, 2012. p 6833–6838. Instruction IS-33, of December 21, 2011, from the Nuclear Safety Council, on radiological criteria for protection against exposure to natural radiation. BOE nº 22 of January 26, 2012. p 6833–6838.
5.
Zurück zum Zitat Council Directive 93/42/EEC of 14 de Junio de 1993, concerning medical devices (OJ L 169, 12.7.1993, p. 1). Council Directive 93/42/EEC of 14 de Junio de 1993, concerning medical devices (OJ L 169, 12.7.1993, p. 1).
8.
Zurück zum Zitat Royal Decree 815/2001, of July 13, on justification for the use of ionizing radiation for radiation protection of people during medical exposures. BOE num. 168, de 14 de Julio de 2001, p. 25591–25594. Royal Decree 815/2001, of July 13, on justification for the use of ionizing radiation for radiation protection of people during medical exposures. BOE num. 168, de 14 de Julio de 2001, p. 25591–25594.
10.
Zurück zum Zitat Garcia CL, Abreu LC, Ramos JLS, Castro CFD, Smiderle FRN, Santos JAD, Becerra IMP: (Influence of Burnout on Patient Safety: Systematic Review and Meta-Analysis. Medicina (Kaunas). 2019;55(9):E553. 10.3390/medicina55090553. Garcia CL, Abreu LC, Ramos JLS, Castro CFD, Smiderle FRN, Santos JAD, Becerra IMP: (Influence of Burnout on Patient Safety: Systematic Review and Meta-Analysis. Medicina (Kaunas). 2019;55(9):E553. 10.3390/medicina55090553.
13.
Zurück zum Zitat José Pardo Masferrer. National Survey on Patient safety in Radiation Oncology. In Carlos Ferrer Albiach and José Pardo Masferrer Editors. Seguridad y Calidad en Oncología Radioterápica. 1st Edition. Madrid. Emiral Ed. 2019. p 91–98. ISBN: 978-84-09-11598-3. José Pardo Masferrer. National Survey on Patient safety in Radiation Oncology. In Carlos Ferrer Albiach and José Pardo Masferrer Editors. Seguridad y Calidad en Oncología Radioterápica. 1st Edition. Madrid. Emiral Ed. 2019. p 91–98. ISBN: 978-84-09-11598-3.
Metadaten
Titel
Safety in radiation oncology: transposition of directive 2013/59/EURATOM in the Spanish Radiation Oncology Departments—recommendations for its adequate and effective application
verfasst von
J. Pardo Masferrer
C. Prieto Martín
C. Ferrer Albiach
Publikationsdatum
22.05.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 11/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02359-x

Weitere Artikel der Ausgabe 11/2020

Clinical and Translational Oncology 11/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.